CN101481338B - Synthesizing method and use of vanadium taurate - Google Patents
Synthesizing method and use of vanadium taurate Download PDFInfo
- Publication number
- CN101481338B CN101481338B CN 200910071481 CN200910071481A CN101481338B CN 101481338 B CN101481338 B CN 101481338B CN 200910071481 CN200910071481 CN 200910071481 CN 200910071481 A CN200910071481 A CN 200910071481A CN 101481338 B CN101481338 B CN 101481338B
- Authority
- CN
- China
- Prior art keywords
- taurine
- vanadium
- reaction solution
- sodium metavanadate
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides a method for synthesizing taurine-vanadium and application thereof. The method consists of the steps of dissolving the taurine in 1-30 times of hot water with the temperature from 60 DEG C to 90 DEG C, neutralizing the PH value to 7-12 by a PH regulator while continuously stirring, adding saturated vanadium compound solution to produce reaction solution of the taurine and the vanadium compound, heating the reaction solution with mol ratio no less than 1:1 to 50-100 DEG C and concentrating the reaction solution, adding 1-5 times of ethanol, cooling, separating out taurine-vanadium precipitation, thus obtaining taurine-vanadium powder by refining and drying. The invention provides a composition taurine-vanadium which is synthesized by the taurine and sodium metavanadate in different proportions and used for curing diabetes. The product of the invention can obviously lower the blood sugar level, thus can be used for curing diabetes. In the method for synthesizing taurine-vanadium, the mol ratio of the taurine and the sodium metavanadate is not less than 1:1, namely, the molarity of the taurine is the same as or more than double the morality of the sodium metavanadate.
Description
(1) technical field
The present invention relates to a kind of is the vanadium compound compound method of title complex with the taurine, particularly treats the application of mellitus.
(2) background technology
The effect of vanadium compound treatment mellitus be that a large amount of institutes confirm both at home and abroad, but the big shortcoming of the big toxicity of its dosage waits to overcome, and seeks the little vanadium compound of the little toxicity of dosage, is that current Glucovance is both at home and abroad developed focus.It is reported that the couplet wheat vanadyl of external invention has got into phase ii clinical trial.
The taurine vanadium is that the taurine by different ratios is part and sodium metavanadate synthetic title complex, and pharmacological experiment study adopts the alloxan diabetes mouse model, with the influence of glucose oxidase enzyme assay survey taurine vanadium to blood glucose in diabetic mice concentration.Large and small dose groups (160,40mg/kg body weight) can significantly reduce blood glucose in diabetic mice concentration (P＜0.05).The diabetes animal model test shows that the taurine vanadium is that diabetic mice is had blood sugar reducing function, and the little toxicity of dosage is little.
At present also not with taurine and sodium metavanadate synthetic title complex taurine vanadium and the report that is used to treat mellitus.
(3) summary of the invention
The object of the present invention is to provide a kind of significant blood sugar reducing function that has, can be used for treating the compound method of the taurine vanadium of mellitus.
The objective of the invention is to realize like this: get taurine and be dissolved in 1-30 times of 60-90 ℃ of hot water, under constantly stirring, use the PH regulator to be neutralized to pH value and be 7-12; The mol ratio that adds saturated vanadium solution generation taurine and vanadium compound is >=1: 1 reaction solution, and reaction solution is heated to 50-100 ℃, concentrates; Add 1-5 times of ethanol; Put coldly, separate out taurine vanadium deposition, refining drying obtains taurine vanadium powder end.
The present invention also has some technical characterictics like this:
1, described PH regulator is an ammoniacal liquor;
2, described vanadium solution is sodium metavanadate or sodium vanadate solution;
3, describedly be heated to 50-100 ℃, in the presence of UW, continue to stir 1-10 hour, reaction solution is concentrated to the 10-100% of stoste volume;
4, described reaction solution adds the 1-5 volume of ethanol after concentrating, and puts coldly, separates out taurine vanadium deposition.
The invention provides a kind of taurine and sodium metavanadate synthetic title complex taurine vanadium of different ratios, be used to treat mellitus.Product of the present invention has significant blood sugar reducing function, can be used for treating mellitus.The mol ratio of taurine and sodium metavanadate is >=1: 1 in the taurine vanadium compound method, and promptly the volumetric molar concentration of the volumetric molar concentration of taurine and sodium metavanadate is identical or greater than more than one times.
The present invention also provides taurine and sodium metavanadate synthetic title complex taurine vanadium to be used to treat the application of mellitus.The research of taurine vanadium hypoglycemic activity:
One, taurine vanadium:
Get taurine and be dissolved in an amount of 60-90 ℃ hot water, under constantly stirring, use ammoniacal liquor to be neutralized to pH value and be 7-12; Add a certain amount of saturated sodium metavanadate solution, taurine and sodium metavanadate mol ratio are 5: 1 reaction solution, and reaction solution is heated to 50-100 ℃; In the presence of hyperacoustic, continue to stir 1-10 hour, reaction solution is concentrated to the 10-100% of stoste volume, adds 1-5 ethanol doubly; Put coldly, separate out taurine vanadium deposition, refining drying obtains taurine vanadium powder end.
Two, dosage design:
Clinical consumption: people's consumption 120mg/ days, experimentation on animals high dosage are that 80 times of clinical consumptions, middle dosage are 40 times, and low dosage is 20 times.
(1) high dosage: 120mg/ people. day ÷ 60kg/ people * 80 times=160mg/kg
(2) dosage in: 120mg/ people. day ÷ 60kg/ people * 40 times=80mg/kg
(3) low dose: 120mg/ people. day ÷ 60kg/ people * 20 times=40mg/kg
Three, TP:
3.1 control drug and reagent
Metformin hydrochloride tablet, lot number: 0511102, the refined pharmaceutical Co. Ltd in Hunan, Hunan; Tetraoxypyrimidine, the Sigma Company products; Serum glucose is measured test kit.Lot number: 2008013, power Bioisystech Co., Ltd product converges in Changchun.
3.2 animal
Kunming mouse, cleaning level, male and female dual-purpose, body weight 18-22g.
3.3 instrument
722 type grating spectrophotometers, analytical instrument factory in Shanghai produces.
4 methods and result
4.1 the foundation of diabetes animal model
The Kunming mouse body weight is (18-22) g; 80, after conforming 3 days under certain temperature, humidity and the illumination condition, abdominal injection tetraoxypyrimidine solution (40mg/kg body weight); The next day 1 time; Successive administration 3 times was measured mouse blood sugar in 6 days after the last administration, and being higher than 11.1mmol/L with blood glucose value is the modeling success.
4.2 divide into groups and test
Choose 50 of the successful diabetic mices of modeling, evenly be divided into 5 groups, be respectively model control group, positive drug group, high, medium and low taurine vanadium group by blood glucose value, get simultaneously 10 not the Kunming mouse of modeling do the normal control group.In the some morning 9 of every day, normal control group, model control group are irritated stomach respectively and are given zero(ppm) water, and the positive drug group is irritated stomach and given N1,N1-Dimethylbiguanide 150mg/kg body weight, the taurine vanadium is high, in, small dose group, irritate respectively that stomach gives 160,80, the 40mg/kg body weight.Administration time is 7 days.After the administration 7 days, at a distance from eating not water proof 12 hours, eye socket is got blood, centrifugal 15 minutes of 3000r/min, and separation of serum is measured glucose level.Detected result all uses X ± SD to represent, carries out the t check to testing each treated animal data.Result such as table 1.
Table 1 taurine vanadium is to the influence of blood glucose in diabetic mice (n=10, X ± SD)
The t check is compared with model control group
*P＜0.05,
*P＜0.01
The result shows that taurine vanadic salts 160,40mg/kg dose groups can significantly reduce blood glucose in diabetic mice concentration.Prompting taurine vanadium has blood sugar reducing function to diabetic mice.
5 conclusions
Above experimental result shows that the taurine vanadium can reduce blood glucose in diabetic mice concentration.Diabetic mice had hypoglycemic activity.
The invention has the beneficial effects as follows: adopt the sodium metavanadate reaction synthesized taurine vanadium complex of taurine and different mol ratio, pharmacological testing shows that the present invention can significantly reduce blood glucose in diabetic mice concentration (P＜0.05).Proof taurine vanadium has blood sugar reducing function safely and effectively to diabetic mice.Can be used for treating mellitus, advantage such as it is little to have dosage, and toxicity is little, and administration time is short, and hypoglycemic effect is obvious.
(4) embodiment
Below in conjunction with specific embodiment the present invention is further described:
Embodiment 1:
Get in 60 ℃ of hot water that taurine is dissolved in 1 times, constantly stirring down, it is 7 that use ammoniacal liquor is neutralized to pH value; Add saturated sodium metavanadate solution, taurine and sodium metavanadate mol ratio are 1: 1 reaction solution, and reaction solution is heated to 50 ℃; In the presence of hyperacoustic, continue to stir 1 hour, reaction solution is concentrated to 10% of stoste volume, adds 1 times of ethanol; Put coldly, separate out taurine vanadium deposition, refining drying obtains taurine vanadium powder end
Embodiment 2:
Get in 70 ℃ of hot water that taurine is dissolved in 5 times, constantly stirring down, it is 8 that use ammoniacal liquor is neutralized to pH value; Add saturated sodium metavanadate solution, taurine and sodium metavanadate mol ratio are 2: 1 reaction solution, and reaction solution is heated to 60 ℃; In the presence of hyperacoustic, continue to stir 2 hours, reaction solution is concentrated to 20% of stoste volume, adds 2 times of ethanol; Put coldly, separate out taurine vanadium deposition, refining drying obtains taurine vanadium powder end.
Embodiment 3:
Get in 80 ℃ of hot water that taurine is dissolved in 10 times, constantly stirring down, it is 9 that use ammoniacal liquor is neutralized to pH value; Add saturated sodium metavanadate solution, taurine and sodium metavanadate mol ratio are 3: 1 reaction solution, and reaction solution is heated to 70 ℃; In the presence of hyperacoustic, continue to stir 5 hours, reaction solution is concentrated to 30% of stoste volume, adds 3 times of ethanol; Put coldly, separate out taurine vanadium deposition, refining drying obtains taurine vanadium powder end.
Embodiment 4:
Get in 90 ℃ of hot water that taurine is dissolved in 15 times, constantly stirring down, it is 10 that use ammoniacal liquor is neutralized to pH value; Add saturated sodium metavanadate solution, taurine and sodium metavanadate mol ratio are 4: 1 reaction solution, and reaction solution is heated to 80 ℃; In the presence of hyperacoustic, continue to stir 7 hours, reaction solution is concentrated to 50% of stoste volume, adds 4 times of ethanol; Put coldly, separate out taurine vanadium deposition, refining drying obtains taurine vanadium powder end.
Embodiment 5:
Get in 80 ℃ of hot water that taurine is dissolved in 18 times, constantly stirring down, it is 11 that use ammoniacal liquor is neutralized to pH value; Add saturated sodium metavanadate solution, taurine and sodium metavanadate mol ratio are 5: 1 reaction solution, and reaction solution is heated to 90 ℃; In the presence of hyperacoustic, continue to stir 8 hours, reaction solution is concentrated to 80% of stoste volume, adds 5 times of ethanol; Put coldly, separate out taurine vanadium deposition, refining drying obtains taurine vanadium powder end.
Embodiment 6:
Get in 90 ℃ of hot water that taurine is dissolved in 20 times, constantly stirring down, it is 12 that use ammoniacal liquor is neutralized to pH value; Add saturated sodium metavanadate solution, taurine and sodium metavanadate mol ratio are 6: 1 reaction solution, and reaction solution is heated to 100 ℃; In the presence of hyperacoustic, continue to stir 9 hours, reaction solution is concentrated to 90% of stoste volume, adds 5 times of ethanol; Put coldly, separate out taurine vanadium deposition, refining drying obtains taurine vanadium powder end.
Embodiment 7:
Get in 90 ℃ of hot water that taurine is dissolved in 15 times, constantly stirring down, it is 7 that use ammoniacal liquor is neutralized to pH value; Add saturated sodium vanadate solution, taurine and sodium vanadate mol ratio are 2: 1 reaction solution, and reaction solution is heated to 100 ℃; In the presence of hyperacoustic, continue to stir 10 hours, reaction solution is concentrated to 100% of stoste volume, adds 1-5 times of ethanol; Put coldly, separate out taurine vanadium deposition, refining drying obtains taurine vanadium powder end.
Claims (3)
1. the compound method of a taurine vanadium is characterized in that, method is: get taurine and be dissolved in an amount of 60-90 ℃ hot water; Under constantly stirring, use ammoniacal liquor to be adjusted to the pH value and be 7-12, add a certain amount of saturated sodium metavanadate solution; Taurine and sodium metavanadate solution mol ratio are 5: 1 reaction solution, and reaction solution is heated to 50-100 ℃, in the presence of hyperacoustic, continue to stir 1-10 hour; Reaction solution is concentrated to the 10-100% of substance hydrops, adds 1-5 times of ethanol, puts cold; Separate out taurine vanadium deposition, refining drying obtains taurine vanadium powder end.
2. the taurine vanadium that compound method according to claim 1 makes.
3. the purposes of the taurine vanadium that compound method according to claim 1 makes in preparation treatment diabetes medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910071481 CN101481338B (en) | 2009-03-03 | 2009-03-03 | Synthesizing method and use of vanadium taurate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910071481 CN101481338B (en) | 2009-03-03 | 2009-03-03 | Synthesizing method and use of vanadium taurate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101481338A CN101481338A (en) | 2009-07-15 |
| CN101481338B true CN101481338B (en) | 2012-12-19 |
Family
ID=40878651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910071481 Expired - Fee Related CN101481338B (en) | 2009-03-03 | 2009-03-03 | Synthesizing method and use of vanadium taurate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101481338B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130323324A1 (en) * | 2012-06-01 | 2013-12-05 | Franco Cavaleri | Vanadium and vanadyl amino acid complexes |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1457773A (en) * | 2003-06-02 | 2003-11-26 | 乐益 | Biguanide vanadium complex granular powder and/or capsule for curing diabetes and its use |
| CN101068769A (en) * | 2004-07-02 | 2007-11-07 | 根梅迪卡治疗公司 | Arakyl amine vanadium (v) salt for treating or/and preventing diabetic |
| CN101238892A (en) * | 2008-03-14 | 2008-08-13 | 卢广荣 | Method for manufacturing nurture from vanadium-rich food and taurine |
-
2009
- 2009-03-03 CN CN 200910071481 patent/CN101481338B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1457773A (en) * | 2003-06-02 | 2003-11-26 | 乐益 | Biguanide vanadium complex granular powder and/or capsule for curing diabetes and its use |
| CN101068769A (en) * | 2004-07-02 | 2007-11-07 | 根梅迪卡治疗公司 | Arakyl amine vanadium (v) salt for treating or/and preventing diabetic |
| CN101238892A (en) * | 2008-03-14 | 2008-08-13 | 卢广荣 | Method for manufacturing nurture from vanadium-rich food and taurine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101481338A (en) | 2009-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104664039B (en) | A kind of saury Mei Lade peptides and its preparation method and application with anti-trioxypurine activity | |
| Yin et al. | Digestion rate of dietary starch affects the systemic circulation of lipid profiles and lipid metabolism-related gene expression in weaned pigs | |
| CN103864950B (en) | A kind of preparation method and applications of low molecule Porphyra haitanensis polysaccharide iron complexes | |
| CN104304577A (en) | Biological beverage with camellia chrysantha as carrier and preparation method thereof | |
| CN102018727A (en) | Preparation method of pearl hydrolysate | |
| CN103040730A (en) | Iron sucrose injection and preparation method thereof | |
| CN101485666B (en) | Application of Gamabufotalin and salt thereof in preparing medicament for treating gynaecologic tumor | |
| Chand et al. | Vitamin B3, niacin | |
| CN114832022A (en) | Preparation of phellinus igniarius sporocarp phenolic active substance and application of phellinus igniarius sporocarp phenolic active substance in regulation of intestinal flora and uric acid metabolism | |
| CN104522750A (en) | Alga healthcare food | |
| CN101481338B (en) | Synthesizing method and use of vanadium taurate | |
| CN111960972A (en) | Preparation process and application of taurine magnesium salt and taurine magnesium complex | |
| CN101991670A (en) | Alpha-gluconase activity inhibiter and application thereof in preparation of diabetic medicament | |
| CN101306014B (en) | Use of brown algae polysaccharide sulfuric acid ester of low molecular weight in preparing medicine for treating diabetic nephropathy | |
| CN104415023A (en) | Composition for preventing or/and treating insulin resistance and related diseases | |
| CN101444599B (en) | Corn silk extract and preparation method thereof and application thereof in preparing drugs for treating gout | |
| CN100534998C (en) | Fructose-1 | |
| CN100502867C (en) | Preparation of sinomenine as antineoplastic medicament | |
| CN103965279A (en) | Novel ginsenoside acid degradation compound as well as preparation method and medical application thereof | |
| CN1844137A (en) | Preparation process of chromium glucosaminic acid and use thereof | |
| CN113493489A (en) | Polypeptide SCGH with sobering function and application thereof | |
| CN102002077A (en) | Novel conjugate of sialic acid-zinc methionine, preparation process and application thereof | |
| CN102093323A (en) | Quercetin preparation method | |
| CN101632641B (en) | Lentinan lyophilized power injection and preparation method thereof | |
| CN101230065B (en) | Method for producing 9-[2(hydroxyl)propyl] adenine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121219 Termination date: 20180303 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |